NEWS for Inovio Pharmaceuticals, Inc. Click here for more Support & Resistance levels for Inovio Pharmaceuticals, Inc.
…
Munafa value: 40 as on 08 Fri Apr 2022.
| Strong resistance | 18 |
|---|---|
| Strong resistance | 14 |
| Strong resistance | 13 |
| Strong resistance | 12 |
| Strong resistance | 11 |
Similarly, Should I buy BNGO?
Based on his analysis, DeGeeter rates BNGO stock as “outperform” with a $14 value. Other analysts are also bullish on the company. Those tracked by the Wall Street Journal have BNGO rated as a consensus “buy” with an average $12 price target.
How many shares does inovio have? Share Statistics
| Avg Vol (3 month) 3 | 4.85M |
|---|---|
| Shares Outstanding 5 | 210.39M |
| Implied Shares Outstanding 6 | N/A |
| Float 8 | 207M |
| % Held by Insiders 1 | 1.65% |
Thereof, Will Ocugen go up?
Long-term Ocugen stock forecast 2022-2025
Algorithm-based forecasting service Wallet Investor gave a positive OCGN stock price forecast. The site predicted that the share price could climb over the next year, to $7.2 by March 2023.
Is BNGO a pump and dump?
BNGO stock has suffered at the hands of a Ritalin-using pump and dump scheme making waves in 2021.
Does ARKG hold BNGO?
Does ARK Invest in BNGO: The Bottom Line. At this time, ARK does not invest in BNGO. With that said, the company does appear to have some promise in its own right. Like all speculative small-cap companies, Bionano Genomics is a risky stock to own.
Will Bionano stock go up?
Bionano Genomics Inc (NASDAQ:BNGO)
The 4 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 7.50, with a high estimate of 14.00 and a low estimate of 6.00. The median estimate represents a +253.77% increase from the last price of 2.12.
Who owns Inovio Pharmaceuticals?
Top 10 Owners of Inovio Pharmaceuticals Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 7.05% | 15,637,463 |
| SSgA Funds Management, Inc. | 6.00% | 13,300,430 |
| The Vanguard Group, Inc. | 4.83% | 10,703,079 |
| D. E. Shaw & Co. LP | 2.70% | 5,985,533 |
When did Ino IPO?
You could have purchased shares of what would later be known as Inovio on Dec. 8, 1998, for a split-adjusted price of $60 per share.
What is target price for Ocugen?
Stock Price Targets
| High | $15.00 |
|---|---|
| Median | $8.00 |
| Low | $6.00 |
| Average | $9.67 |
| Current Price | $3.4800 |
Is Ocugen a good long term investment?
Ocugen is a dangerous investment, especially given it is unprofitable, it’s burning through money, and investors have been wary of growth stocks of late. Unless you’re prepared for the risk, you’re better off avoiding Ocugen.
Is VXRT a good stock to buy?
Is VAXART Stock a good buy in 2022, according to Wall Street analysts? The consensus among 4 Wall Street analysts covering (NASDAQ: VXRT) stock is to Strong Buy VXRT stock.
Will BNGO get FDA approval?
The Food and Drug Administration has not yet approved the device for use as a medical diagnostic tool in the U.S. However, healthcare entities can still use it for research purposes. The lack of FDA approval has also not hindered sales of the Saphyr in other countries.
Is BNGO a meme stock?
Admittedly, it has been a while since Bionano Genomics (NASDAQ:BNGO) stock has been a “hot stock,” a “meme stock” or whatever you want to call it. Since its big drop in late February and early March, the market has had mixed feelings about this life sciences company.
Who owns Bionano genomics?
Top 10 Owners of Bionano Genomics Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 5.74% | 16,609,007 |
| The Vanguard Group, Inc. | 4.86% | 14,064,639 |
| SSgA Funds Management, Inc. | 2.49% | 7,198,880 |
| Geode Capital Management LLC | 1.63% | 4,714,883 |
Does Ark buy BNGO?
Investors who want to start a position in BNGO may want to act before Ark does, because once Ark announces it has bought, expect shares of Bionano to shoot through the roof.
…
Rate this article.
| Perf. YTD | -36.05% |
|---|---|
| 52W low | -8.02% |
| PE Ratio | 0 |
| MKT Cap | 506.82M |
• 22 févr. 2021
What ETF is BNGO in?
ETF.com Insight
The largest ETF holder of BNGO is the iShares Russell 2000 ETF (IWM), with approximately 6.52M shares.
Does BNGO have FDA approval?
The Food and Drug Administration has not yet approved the device for use as a medical diagnostic tool in the U.S. However, healthcare entities can still use it for research purposes. The lack of FDA approval has also not hindered sales of the Saphyr in other countries.
Who is buying BNGO stock?
Top 10 Owners of Bionano Genomics Inc
| Stockholder | Stake | Shares bought / sold |
|---|---|---|
| BlackRock Fund Advisors | 5.74% | +407,569 |
| The Vanguard Group, Inc. | 4.86% | -202,320 |
| SSgA Funds Management, Inc. | 2.49% | -323,972 |
| Geode Capital Management LLC | 1.63% | +42,831 |
Who owns Nvax?
Top 10 Owners of Novavax Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| The Vanguard Group, Inc. | 8.98% | 6,787,173 |
| BlackRock Fund Advisors | 4.70% | 3,549,765 |
| RA Capital Management LP | 2.78% | 2,097,794 |
| SSgA Funds Management, Inc. | 2.51% | 1,899,220 |
Join TheMoney.co community and don’t forget to share this post !